Ray Kurzweil Joins Subsense to Develop AI-Driven Nasal Nanoparticle Brain Interface

Thumbnail Image

The information displayed in the AIM should not be reported as representing the official views of the OECD or of its member countries.

AI pioneer Ray Kurzweil has joined Subsense, a Silicon Valley startup developing a non-surgical brain-computer interface that uses inhaled nanoparticles and AI to read and stimulate neural activity. The technology, still in preclinical stages, raises future safety and reliability concerns but has not yet caused harm.[AI generated]

Why's our monitor labelling this an incident or hazard?

The article clearly involves an AI system in development (brain-computer interface with AI integration). The technology is invasive and experimental, involving nanoparticles and neural stimulation, which could plausibly lead to health or ethical harms in the future. However, no actual harm or incident is reported, and the technology is still in pre-clinical stages. Thus, it does not meet the criteria for an AI Incident. It is not Complementary Information because the article is not about a response or update to a prior incident but about the development of a new technology. It is not Beneficial Use because the technology is not yet deployed as a countermeasure to an external harm, and no harm is being addressed currently. Therefore, the classification as AI Hazard is appropriate.[AI generated]
AI principles
SafetyPrivacy & data governance

Industries
Healthcare, drugs, and biotechnology

Business function:
Research and development

AI system task:
Recognition/object detectionGoal-driven organisation


Articles about this incident or hazard